Eladocagene exuparvovec
Eladocagene exuparvovec is a gene therapy product developed by BioMarin Pharmaceutical for the treatment of Phenylketonuria. It is currently in the clinical trial phase and has not yet been approved for use by any regulatory authority.
Overview[edit | edit source]
Eladocagene exuparvovec is a recombinant adeno-associated virus vector-based gene therapy. It is designed to deliver a functional copy of the phenylalanine hydroxylase (PAH) gene to liver cells. The PAH gene is responsible for the production of an enzyme that breaks down the amino acid phenylalanine. In individuals with phenylketonuria, a mutation in the PAH gene leads to a deficiency of this enzyme, resulting in the accumulation of phenylalanine in the body.
Mechanism of Action[edit | edit source]
Eladocagene exuparvovec works by introducing a functional copy of the PAH gene into the patient's liver cells. This is achieved through the use of a recombinant adeno-associated virus vector, which is engineered to carry the PAH gene. Once inside the liver cells, the PAH gene is incorporated into the cell's own DNA, enabling the cell to produce the PAH enzyme and thereby break down phenylalanine.
Clinical Trials[edit | edit source]
As of 2021, eladocagene exuparvovec is in Phase 3 clinical trials. The primary endpoint of these trials is the change in blood phenylalanine levels from baseline. Secondary endpoints include the change in dietary phenylalanine tolerance and the change in neuropsychiatric symptoms associated with phenylketonuria.
Potential Impact[edit | edit source]
If approved, eladocagene exuparvovec could provide a significant advancement in the treatment of phenylketonuria. Current treatments for this condition primarily involve dietary restrictions to limit phenylalanine intake. However, these dietary restrictions can be difficult to adhere to and do not address the underlying genetic defect. By providing a functional PAH gene, eladocagene exuparvovec has the potential to address the root cause of phenylketonuria and improve patient outcomes.
See Also[edit | edit source]
- Gene therapy
- Phenylketonuria
- BioMarin Pharmaceutical
- Clinical trial
- Adeno-associated virus
- Phenylalanine hydroxylase
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD